A Novel and Integrated Approach for the Identification and Characterization of Drug-induced Cardiac Toxicity in the Dog

被引:19
作者
Casartelli, Alessandro [1 ]
Lanzoni, Anna [1 ]
Comelli, Rodolfo [1 ]
Crivellente, Federica [1 ]
Defazio, Rossella [1 ]
Dorigatti, Roberto [1 ]
Fasdelli, Nicola [1 ]
Faustinelli, Ivo [1 ]
Pagliarusco, Sabrina [2 ]
Tontodonati, Marcello [1 ]
Cristofori, Patrizia [1 ]
机构
[1] GlaxoSmithKline Res Ctr, Dept Safety Assessment, Verona, Italy
[2] GlaxoSmithKline Res Ctr, Drug Metab & Pharmacokinet Dept, Verona, Italy
关键词
brain natriuretic peptide; cardiac toxicity; cardiotoxicity; cardiac troponin I; Casopitant; dog; phospholipidosis; preclinical development; CATIONIC AMPHIPHILIC DRUG; INDUCED PHOSPHOLIPIDOSIS; NATRIURETIC PEPTIDE; AMIODARONE; PLASMA; HEART; BIOMARKER;
D O I
10.1177/0192623310390704
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Cardiovascular toxicity represents one of the major reasons for the termination of the development of drugs, even in late development phases. This growing issue is often not restricted to specific therapeutic areas, and it is gaining critical importance, in particular for chronically administered drugs, highlighting the limitations in terms of sensitivity of the current investigational paradigms. Furthermore, drug-related changes may become evident after long-term administration for different reasons, including accumulation of the drug in the heart. This article describes how the integrated use of investigational tools represents a powerful approach for the early identification and characterization of cardiotoxicity in preclinical development. Cardiac changes were observed in the dog after long-term oral administration of casopitant, a neurokinin 1 receptor antagonist, developed for the treatment of depression and anxiety. Different approaches and sensitive biomarkers were used in a time-course study to investigate the onset, progression, and reversibility of the lesion. The integrated evaluation of cardiovascular parameters, electron microscopy, troponin I, and natriuretic peptide results highlighted any minimal early changes, allowing the full and deep characterization of the lesion. The outcome of this study was the driver for drug development decision making on casopitant and backup drugs.
引用
收藏
页码:361 / 371
页数:11
相关论文
共 32 条
  • [1] Drug-induced phospholipidosis
    Anderson, Nora
    Borlak, Juergen
    [J]. FEBS LETTERS, 2006, 580 (23) : 5533 - 5540
  • [2] Breyer U., 1974, TISSUE ACCUMULATION
  • [3] CARDIOVASCULAR EFFECTS OF TRICYCLIC AND TETRACYCLIC ANTIDEPRESSANTS
    BURCKHARDT, D
    RAEDER, E
    MULLER, V
    IMHOF, P
    NEUBAUER, H
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1978, 239 (03): : 213 - 216
  • [4] Car B., 2006, AM DRUG DISCOVERY, V1, P53
  • [5] Cheville F. N., 1994, ULTRASTRUCTURAL PATH
  • [6] EXPERIMENTAL MYOPATHY INDUCED BY AMPHIPHILIC CATIONIC COMPOUNDS INCLUDING SEVERAL PSYCHOTROPIC-DRUGS
    DRENCKHAHN, D
    LULLMANNRAUCH, R
    [J]. NEUROSCIENCE, 1979, 4 (04) : 549 - 562
  • [7] Plasma pro-B-type natriuretic peptide in the general population: screening for left ventricular hypertrophy and systolic dysfunction
    Goetze, Jens Peter
    Mogelvang, Rasmus
    Maage, Lars
    Scharling, Henrik
    Schnohr, Peter
    Sogaard, Peter
    Rehfeld, Jens F.
    Jensen, Jan Skov
    [J]. EUROPEAN HEART JOURNAL, 2006, 27 (24) : 3004 - 3010
  • [8] Cationic amphiphilic drug-induced phospholipidosis
    Halliwell, WH
    [J]. TOXICOLOGIC PATHOLOGY, 1997, 25 (01) : 53 - 60
  • [9] Drug-induced phospholipidosis is caused by blockade of mannose 6-phosphate receptor-mediated targeting of lysosomal enzymes
    Ikeda, Kazuhiko
    Hirayama, Masahiro
    Hirota, Yuko
    Asa, Erika
    Seki, Jiro
    Tanaka, Yoshitaka
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2008, 377 (01) : 268 - 274
  • [10] Prognostic value of combination of cardiac troponin T and B-type natriuretic peptide after initiation of treatment in patients with chronic heart failure
    Ishii, J
    Cui, W
    Kitagawa, F
    Kuno, T
    Nakamura, Y
    Naruse, H
    Mori, Y
    Ishikawa, T
    Nagamura, Y
    Kondo, T
    Oshima, H
    Nomura, M
    Ezaki, K
    Hishida, H
    [J]. CLINICAL CHEMISTRY, 2003, 49 (12) : 2020 - 2026